Pterygium

1. What is Pterygium?
2. Pathophysiology
3. Risk Factors
4. Symptoms and Diagnosis
5. Conservative Management
6. Surgical Treatment
7. Emerging and Supportive Therapies
8. Nutrition and Lifestyle
9. Prognosis and Recurrence Prevention
10. Cautions and Considerations
11. References and Research
12. Connections
13. Featured Videos

What is Pterygium?

Pterygium (pronounced teh-RIJ-ee-um) is a fibrovascular growth of conjunctival tissue that invades the cornea, typically advancing from the nasal side of the eye toward the center. The word comes from the Greek pterygion, meaning "little wing," describing the triangular or wing-shaped appearance of the growth on the white part of the eye.

Pterygium is benign — it is not a cancer — but it can cause significant problems: progressive astigmatism that blurs vision, chronic surface irritation, cosmetic distress, and in advanced cases, direct encroachment over the pupil causing visual impairment. Colloquially known as "surfer's eye," it is strongly associated with cumulative UV-B radiation exposure, making it disproportionately common in people who spend extensive time outdoors.

Globally, prevalence varies dramatically by geography and UV exposure:

• Tropical and equatorial regions: 10–30% prevalence in the adult population
• Temperate climates: 1–2% prevalence
• Pterygium Belt: the zone between latitudes 37°N and 37°S bears the highest global burden

Pterygium vs. Pinguecula: Both arise from UV damage to the conjunctiva. A pinguecula is a yellowish-white deposit that stays confined to the conjunctiva and does not cross onto the cornea. A pterygium extends past the limbus (the border between conjunctiva and cornea) and invades the corneal surface — this crossing is the defining distinction. Pinguecula may precede pterygium formation, but most pingueculae never progress to pterygium.

Back to Table of Contents

Pathophysiology

The formation and growth of pterygium involves UV-driven molecular injury, limbal stem cell failure, enzymatic matrix breakdown, and chronic inflammation operating together over years.

UV-B radiation and limbal stem cell dysfunction: The limbal stem cells at the corneoscleral junction normally replenish the corneal epithelium and form a biological barrier preventing conjunctival cells from crossing onto the cornea. Cumulative UV-B radiation disrupts this barrier. UV-B induces somatic mutations — particularly in the TP53 tumor suppressor gene — in limbal epithelial basal cells. These mutations reduce apoptosis and allow abnormal, proliferative conjunctival-like cells to escape the limbal niche and invade the corneal surface.

Matrix metalloproteinases (MMPs) and Bowman's layer degradation: Once fibrovascular tissue reaches the limbus, progression onto the cornea requires dissolving Bowman's layer, the acellular collagen barrier on the corneal surface. Pterygium cells overproduce MMP-1, MMP-2, and MMP-9 — collagenases that degrade Bowman's layer collagen, clearing a path for fibrovascular invasion. Elevated MMP expression is found throughout active pterygium tissue.

VEGF and neovascularization: Vascular endothelial growth factor (VEGF) is upregulated in pterygium stroma, driving the formation of new blood vessels (the red, inflamed appearance). VEGF also acts as a pro-proliferative signal for pterygium fibroblasts. Anti-VEGF therapies exploit this mechanism.

Inflammatory mediators: Pterygium tissue is rich in inflammatory cytokines — interleukin-1 (IL-1), tumor necrosis factor-alpha (TNF-alpha), and transforming growth factor-beta (TGF-beta). These cytokines activate fibroblasts, driving the deposition of fibrovascular stroma that gives the growth its firm consistency and promotes progressive extension.

Tear film desiccation: The nasal cornea experiences chronic desiccation because tear film is distributed asymmetrically, with the nasal cornea receiving less coverage than the temporal side during blinking. This desiccation promotes epithelial microtrauma, amplifies UV damage, and triggers the inflammatory cascade — explaining why pterygium is almost always nasal (pterygium can be temporal but it is far less common).

Back to Table of Contents

Risk Factors

Pterygium is a multifactorial disease, but UV-B exposure dominates the risk profile.

• UV-B radiation (primary risk factor): Cumulative lifetime UV-B exposure is the single most important risk factor. Risk increases with proximity to the equator, altitude (10% more UV per 1,000 meters), and time spent outdoors without eye protection.
• Geography: Living within the "Pterygium Belt" (latitudes 37°N–37°S) carries substantially higher risk. Australia, India, Southeast Asia, East Africa, and the Caribbean show the highest prevalence.
• Occupation: Farming, fishing, construction, roofing, lifeguarding, and military service involve intense prolonged UV exposure. Dust and particulate matter in outdoor work environments add mechanical irritation.
• Dry, dusty, windy environments: Accelerate tear film evaporation and corneal desiccation, amplifying UV-driven injury at the limbus.
• Age: Incidence peaks between 20 and 40 years — the period of highest occupational and recreational UV exposure. Prevalence continues to rise with age as cumulative damage accumulates.
• Male sex: Historically higher in men due to more outdoor occupational exposure. The sex gap has been narrowing as women's occupational and recreational UV exposure has increased.
• Genetic predisposition: Family history confers increased risk. HLA associations (particularly HLA-DR) have been identified. Familial clustering suggests a hereditary component independent of shared UV exposure environments.
• Nutritional deficiencies: Low dietary vitamin A (impairs conjunctival epithelial integrity and goblet cell maintenance) and vitamin C (reduces antioxidant capacity against UV-induced oxidative stress) have been associated with higher pterygium prevalence in some studies.
• Contact lens wear: May contribute via chronic ocular surface irritation, though evidence is limited.

Back to Table of Contents

Symptoms and Diagnosis

Clinical presentation: Many early pterygia are asymptomatic, discovered incidentally on routine eye examination or noticed as a cosmetic change — a reddish or pinkish triangular growth on the nasal white of the eye. As the pterygium enlarges, symptoms develop:

• Foreign body sensation, itching, and burning: Caused by disruption of the normal smooth corneal surface and tear film instability at the pterygium-cornea interface.
• Redness and injection: The fibrovascular tissue is visibly vascular, and episodes of acute inflammation cause pronounced redness.
• Induced astigmatism: As the pterygium approaches and crosses the visual axis, it mechanically distorts the corneal curvature, inducing progressive myopic (with-the-rule) astigmatism. This is the most functionally significant early complication.
• Blurred or distorted vision: Occurs when astigmatism increases or when the pterygium grows over the pupillary axis, scattering and blocking incoming light.
• Restricted eye movement: Large pterygia can scar Tenon's capsule and the medial rectus muscle, limiting abduction (outward gaze) and causing diplopia.
• Contact lens intolerance: Surface irregularity from even a small pterygium prevents comfortable lens fitting.

Grading (Tan classification):

• Grade 1: Pterygium does not extend beyond the limbus; episcleral vessels visible through the tissue (atrophic)
• Grade 2: Extends onto cornea, partially obscures episcleral vessels; does not reach pupil margin
• Grade 3: Extends to within 2 mm of the pupil margin; episcleral vessels completely obscured
• Grade 4: Growth extends over the pupil margin or pupil center

Diagnostic workup:

• Slit-lamp examination: Clinical diagnosis; characterize size, vascularity, thickness, and measure distance from limbus to pupil margin.
• Corneal topography: Quantifies and maps induced astigmatism; essential for surgical planning and monitoring progression in watch-and-wait cases.
• Visual acuity testing: Documents functional impact; refraction identifies correctability of induced astigmatism.
• Probe test (distinguishes from pseudopterygium): Pass a fine probe under the edge of the lesion at the limbus. True pterygium slides freely under the probe; pseudopterygium (post-inflammatory conjunctival adhesion) is adherent to the underlying cornea and does not slide.

Differential diagnosis:

• Pseudopterygium: Follows ocular surface inflammation (chemical burn, severe infection); adherent at head only; does not extend under probe
• Ocular surface squamous neoplasia (OSSN) / conjunctival intraepithelial neoplasia (CIN): Gelatinous, leukoplakic, or papillary surface; may be vascularized; biopsy required if atypical features present
• Phlyctenular conjunctivitis: Nodular, often at limbus; associated with hypersensitivity reaction; lacks fibrovascular invasion of cornea
• Pannus: Superficial fibrovascular ingrowth from superior limbus; associated with contact lens hypoxia or trachoma; not triangular

Back to Table of Contents

Conservative Management

Many pterygia, particularly small and stable ones, can be managed without surgery. The goals are symptom relief, slowing progression, and UV protection to prevent growth.

Lubrication: Preservative-free artificial tears are the first-line symptomatic treatment. They reduce desiccation-driven irritation at the pterygium surface, stabilize the tear film, and may slow progression by reducing the chronic UV-amplified desiccation stress at the limbus. Used as frequently as needed — 4–8 times daily in symptomatic patients. Gel formulations (carboxymethylcellulose, hyaluronate) are preferred at night. Avoid preserved drops with BAK (benzalkonium chloride), which further destabilizes the ocular surface.

UV protection (most important preventive measure):

• UV-400 rated wraparound sunglasses block UV-A and UV-B from all angles including temporal and superior approaches
• Wide-brim hats (minimum 3-inch brim) reduce superior UV exposure by approximately 50%
• These measures are equally important after surgical excision — recurrence rates are substantially higher in patients who do not consistently use UV protection post-operatively

Topical corticosteroids: Short-term use (1–2 weeks) for acute inflammatory episodes — pterygium flares with injection, chemosis, and discomfort. Not appropriate for chronic use due to risks of intraocular pressure elevation, posterior subcapsular cataract formation, and secondary infection. They do not prevent long-term pterygium growth when used chronically.

Topical NSAIDs: Ketorolac 0.5% or diclofenac 0.1% reduce surface inflammation and discomfort. Useful for symptomatic control with a better safety profile than chronic steroids. Do not alter growth trajectory.

Mast cell stabilizers and antihistamines: When there is an allergic conjunctivitis component — olopatadine, ketotifen — can reduce itching and conjunctival hyperemia that exacerbates pterygium symptoms. Particularly relevant in patients with seasonal allergic conjunctivitis.

Monitoring for progression: Patients managed conservatively should have annual corneal topography. Rapid astigmatic progression, growth toward the visual axis, or worsening symptoms are indications to reassess surgical timing.

Back to Table of Contents

Surgical Treatment

Indications for surgery:

• Encroachment on the visual axis (within 2–3 mm of pupil margin or over pupil)
• Induced astigmatism >2 diopters that is progressively worsening
• Persistent, intractable symptoms despite maximal conservative therapy
• Significant cosmetic concern causing psychosocial distress
• Restricted extraocular motility or diplopia
• Inability to fit or wear contact lenses
• Progressive growth documented on serial topography

Bare sclera excision alone — abandoned: Simple excision of the pterygium leaving the underlying sclera bare was the earliest surgical approach. Recurrence rates of 40–80% have led to its abandonment as a stand-alone procedure. It is only occasionally used for very small primary pterygia in elderly low-recurrence-risk patients.

Conjunctival autograft (CAG) — gold standard: A free graft of bulbar conjunctiva is harvested from the superotemporal quadrant of the same eye (away from the surgical site and the limbus, preserving limbal stem cells at that quadrant). The graft is transposed to cover the bare sclera after pterygium excision, with limbal edge of the graft sutured to the limbal edge of the excision site. This restores the conjunctival barrier and supplies healthy, UV-undamaged epithelium.

• Fixation with fibrin glue (Tisseel): Reduces operative time, patient discomfort, and subconjunctival fibrosis compared with sutures. Recurrence rates 2–10%.
• Fixation with absorbable sutures (Vicryl 8-0): Equivalent oncologic outcomes; more widely available; slightly more postoperative discomfort and inflammation.

Amniotic membrane transplantation (AMT): Preserved amniotic membrane (from elective cesarean sections) is an alternative graft material when insufficient healthy superior conjunctiva is available — for example, in patients who have had prior glaucoma filtering surgery (trabeculectomy blebs), prior conjunctival scarring, or in recurrent pterygium cases. Amniotic membrane has anti-inflammatory, anti-fibrotic, and pro-epithelialization properties. Recurrence rates with AMT are higher than CAG (approximately 10–25%) but superior to bare sclera.

Adjuvant therapies to reduce recurrence:

• Mitomycin C (MMC 0.02%): An antimetabolite that inhibits fibroblast proliferation. Applied intraoperatively on a sponge to the bare sclera for 3–5 minutes, then thoroughly irrigated. Reduces recurrence to 0–15% when combined with CAG. However, MMC carries serious risks: scleral melting (necrotizing scleritis), corneal dellen (sterile corneal thinning at the graft edge), and secondary infection. Use the minimum effective dose and duration. MMC must never be dispensed as a patient take-home drop — professional intraoperative application only.
• 5-Fluorouracil (5-FU): Subconjunctival injection post-operatively; inhibits fibroblast proliferation. Lower risk than MMC but less extensively studied. Used more often for recurrent pterygium.
• Beta-irradiation: Historically used post-operatively to reduce recurrence. Largely replaced by MMC and CAG due to risk of radiation keratopathy, scleral necrosis, and secondary glaucoma with long-term follow-up.
• Subconjunctival anti-VEGF (bevacizumab): Off-label; reduces vascularity, may reduce recurrence; investigational but increasingly used pre-operatively to reduce pterygium vascularity and post-operatively to manage early recurrence signs.

Recurrent pterygium: Surgery for recurrent pterygium is technically more challenging due to subconjunctival fibrosis and scarring. Amniotic membrane graft is preferred when insufficient autograft conjunctiva is available. Excess cautery should be avoided — heat-induced scleral damage compounds the risk of scleral melting, especially when MMC is used. Autologous serum eye drops post-operatively support healing.

Back to Table of Contents

Emerging and Supportive Therapies

Autologous serum eye drops (ASEDs): Made from the patient's own blood serum, ASEDs contain epidermal growth factor (EGF), nerve growth factor (NGF), substance P, fibronectin, and immunoglobulins that support corneal epithelial healing and suppress inflammation. Used post-operatively in patients with persistent dryness, poor epithelial healing, or severe dry eye disease. Concentration typically 20–50%; refrigerated; used 4–8 times daily. Particularly valuable in recurrent pterygium cases with significant limbal stem cell compromise.

Topical anti-VEGF (bevacizumab): Off-label subconjunctival or topical bevacizumab has been studied for reduction of pterygium vascularity and size without surgery. Results show reduction in redness and mild reduction in size, but no evidence that it prevents progression to the cornea long-term. Most useful as pre-surgical preparation in highly vascular pterygia to reduce intraoperative bleeding, or for managing post-surgical recurrence signs before committing to reoperation.

Limbal stem cell transplantation: In cases of extensive limbal stem cell deficiency from recurrent pterygium, chemical injury, or multiple surgeries, cultivated limbal epithelial transplantation (CLET) or simple limbal epithelial transplantation (SLET) can restore the limbal barrier. These are advanced procedures performed at specialized corneal centers and are not first-line pterygium treatments.

Corneal tattooing: For patients with residual corneal scarring after pterygium removal who are not candidates for further corneal surgery, tattooing of the opaque scar with India ink or iron oxide has been used for cosmetic improvement. This is rare and reserved for selected cases.

Investigational approaches: Research is ongoing into targeting the molecular pathways driving pterygium — including MMP inhibitors, TGF-beta blockers, and targeted therapy against the p53 mutation pathway. None are yet in clinical practice.

Back to Table of Contents

Nutrition and Lifestyle

While UV protection remains the cornerstone of pterygium prevention and recurrence reduction, nutritional status affects the health of the ocular surface and the eye's antioxidant defenses against UV-induced damage.

Vitamin A: Essential for maintaining conjunctival goblet cell density and producing the mucin layer of the tear film. Goblet cell depletion from vitamin A deficiency leads to severe dry eye and chronic desiccation stress that amplifies UV damage at the limbus. Even subclinical vitamin A insufficiency in populations with predominantly plant-based diets can compromise ocular surface integrity. Food sources: liver, eggs, dairy, orange and yellow vegetables (as beta-carotene).

Vitamin C: A major antioxidant in the aqueous humor and corneal epithelium. UV-B generates reactive oxygen species (ROS) in limbal cells; ascorbate quenches ROS, protecting against UV-induced mutation. Population studies have found inverse associations between dietary vitamin C intake and pterygium prevalence. Food sources: citrus fruits, bell peppers, kiwi, broccoli, strawberries.

Omega-3 fatty acids (EPA and DHA): Reduce systemic and ocular surface inflammation. Support meibomian gland function and tear film lipid layer stability, reducing evaporative dry eye that drives desiccation stress. Observational studies suggest omega-3 supplementation improves dry eye disease metrics that overlap with pterygium risk factors. Food sources: oily fish (salmon, sardines, mackerel), flaxseed, walnuts.

Lutein and zeaxanthin: These macular carotenoids also concentrate in the cornea and conjunctiva, where they absorb UV and blue-wavelength light that would otherwise damage limbal cells. The eye cannot synthesize lutein or zeaxanthin — they must come entirely from diet. Food sources: kale, spinach, eggs, corn, orange peppers.

Zinc: Co-factor for ocular antioxidant enzymes (superoxide dismutase) and required for vitamin A metabolism in the eye. Low zinc status correlates with ocular surface disease. Food sources: oysters, beef, pumpkin seeds, legumes.

Lifestyle recommendations:

• UV-400 wraparound sunglasses — every day outdoors, including overcast days (clouds block only 20–40% of UV-B)
• Wide-brim hat — reduces overhead and lateral UV reaching the eye
• Avoid smoking — nicotine and acrolein in cigarette smoke generate ROS in corneal cells and deplete systemic antioxidant capacity, potentiating UV-induced limbal damage
• Maintain good hydration and use preservative-free lubricating drops in dry, dusty, or air-conditioned environments
• Schedule outdoor work during early morning or late afternoon when UV index is lower

Back to Table of Contents

Prognosis and Recurrence Prevention

Without surgery: Small, non-progressive pterygia can remain stable for years or decades. However, there is no reliable clinical predictor of which pterygia will grow and which will remain static. Annual monitoring with corneal topography is essential for small pterygia being observed.

Surgical outcomes: When surgery is performed before the pterygium reaches the visual axis, visual prognosis is excellent. Induced astigmatism often partially or fully resolves after excision, though the amount of resolution depends on how long the pterygium was distorting the cornea and whether permanent Bowman's layer changes have occurred.

Recurrence rates by technique:

• Bare sclera excision alone: 40–80%
• Bare sclera + MMC: 15–35%
• Amniotic membrane transplantation (AMT): 10–25%
• Conjunctival autograft (CAG) with sutures: 5–15%
• Conjunctival autograft (CAG) with fibrin glue: 2–10%
• CAG + intraoperative MMC: 0–5% (best recurrence prevention; higher complication risk)

Risk factors for recurrence:

• Young age (under 40) — more robust fibroblast response and longer remaining lifetime UV exposure
• Male sex (historically; gap narrowing)
• Continued occupational UV exposure without adequate eye protection post-operatively
• Nasal location (as opposed to temporal — nasal pterygia are more aggressive)
• Aggressive histopathology — high mitotic index, vascular density, inflammatory infiltrate in excised tissue
• Inadequate or omitted adjuvant therapy

Timing of recurrence: The vast majority of recurrences appear within 6–12 months of surgery. Late recurrences beyond 18 months are uncommon. This informs post-operative follow-up scheduling — monthly for 3 months, then every 3–6 months for the first 2 years.

Second surgery: More technically challenging due to subconjunctival fibrosis and conjunctival scarring. Complication risk is higher, and success rates lower. Prevention of the first recurrence is strongly preferable to managing the second operation.

Back to Table of Contents

Cautions and Considerations

Topical corticosteroids — use only short-term: Chronic steroid use for pterygium control is inappropriate. Risks include steroid-induced ocular hypertension (particularly in steroid responders), posterior subcapsular cataract formation, and susceptibility to herpetic keratitis. Always use a defined short course (1–2 weeks) for acute flares only.

Mitomycin C — professional application only: MMC is a potent antimetabolite with serious ocular side effects including scleral melting, corneal dellen formation, secondary infection, and anterior segment ischemia when overused. It must never be dispensed as a patient take-home drop or prescribed for self-administration. Ophthalmologists apply it intraoperatively under controlled conditions at the minimum effective dose and contact time, followed by thorough irrigation.

Do not delay surgery until complete visual axis involvement: The common patient hesitancy — "I'll wait until my vision is affected" — leads to larger pterygium at the time of surgery, increased astigmatism that may not fully resolve, greater graft size requirements, and lower likelihood of complete vision rehabilitation. Earlier intervention when the pterygium approaches (but has not yet reached) the visual axis yields the best functional outcomes.

Post-operative UV protection is mandatory: Pterygium recurrence risk is lifelong and UV-driven. Patients must understand that surgery removes the current pterygium but does not eliminate the underlying UV-sensitive biology of their limbal epithelium. Consistent UV-400 sunglasses and hat use must be maintained permanently, not just during the post-operative healing period.

Distinguish from ocular surface squamous neoplasia (OSSN): Pterygium and OSSN can look similar on casual examination, especially early gelatinous OSSN. Red flags for OSSN include: papillary or gelatinous surface texture, leukoplakia (white plaques), prominent feeder vessels, unusual location (not nasal), rapid growth, and patient age under 50 with no significant UV exposure history. Atypical lesions should be biopsied before surgical excision to direct pathology and ensure oncologic management if needed.

Ping-pong surgery: Operating on bilateral pterygia simultaneously (or in rapid succession) is controversial. Staggering surgery by at least 6 weeks between eyes is generally recommended so that the visual rehabilitation from the first eye is confirmed before the second eye's healing period begins.

Back to Table of Contents

References and Research

1. Chui J et al. The pathogenesis of pterygium: current concepts and their therapeutic implications. Ocul Surf. 2008;6(1):24–43. PMID 18264653. doi:10.1016/S1542-0124(12)70170-X
2. Clearfield E et al. Conjunctival autograft for pterygium. Cochrane Database Syst Rev. 2016;2:CD011349. PMID 26867004. doi:10.1002/14651858.CD011349.pub2
3. Dushku N, Reid TW. Immunohistochemical evidence that human pterygia originate from an invasion of vimentin-expressing altered limbal epithelial basal cells. Curr Eye Res. 1994;13(7):473–481. PMID 7956277. doi:10.3109/02713689408999878
4. Hirst LW. The treatment of pterygium. Surv Ophthalmol. 2003;48(2):145–180. PMID 12686302. doi:10.1016/S0039-6257(02)00463-0
5. Liu L et al. Ultraviolet radiation and the eye: an overview of published research. Optom Vis Sci. 1997;74(6):415–428. PMID 9232387. doi:10.1097/00006324-199706000-00016
6. Saw SM, Tan D. Pterygium: prevalence, demography and risk factors. Ophthalmic Epidemiol. 1999;6(3):219–228. PMID 10487821. doi:10.1076/opep.6.3.219.1511
7. Teng CC et al. Amniotic membrane transplantation for conjunctival reconstruction in patients with recurrent pterygium. Ophthalmology. 2000;107(8):1413–1419. PMID 10919866. doi:10.1016/S0161-6420(00)00172-3
8. Ti SE, Tan D. Tectonic corneal lamellar grafting for severe scleral melting after pterygium surgery. Ophthalmology. 2003;110(6):1126–1136. PMID 12799235. doi:10.1016/S0161-6420(03)00262-4
9. Koranyi G et al. Conjunctival autograft transplantation for pterygium surgery: fibrin glue versus Vicryl sutures for fixation. Acta Ophthalmol Scand. 2005;83(3):298–301. PMID 15948781. doi:10.1111/j.1600-0420.2005.00455.x
10. Frucht-Pery J, Ilsar M. The use of low-dose mitomycin C for prevention of recurrent pterygium. Ophthalmology. 1994;101(4):759–762. PMID 8152772. doi:10.1016/S0161-6420(94)31264-9
11. Cardillo JA et al. Post-operative use of beta radiation as adjuvant treatment after excision of pterygia. Ophthalmic Surg Lasers. 1995;26(3):278–283. PMID 7773435. PubMed 7773435
12. Anguria P et al. The role of heredity in pterygium development. Surv Ophthalmol. 2014;59(5):543–554. PMID 25037530. doi:10.1016/j.survophthal.2014.01.002

PubMed Topic Searches

1. Pterygium pathogenesis
2. Pterygium conjunctival autograft
3. Pterygium mitomycin C recurrence
4. Pterygium UV radiation limbal stem cells
5. Pterygium amniotic membrane transplant
6. Pterygium fibrin glue vs sutures
7. Pterygium anti-VEGF bevacizumab
8. Pterygium recurrence risk factors
9. Pterygium epidemiology prevalence
10. OSSN vs pterygium differential

Back to Table of Contents

Connections

• Dry Eye Disease
• Corneal Ulcer
• Corneal Dystrophy
• Conjunctivitis
• Cataracts
• Keratoconus
• Glaucoma
• Ophthalmology — All Conditions
• Vitamin A
• Vitamin C
• Zinc
• Omega-3 Fatty Acids

Back to Table of Contents

Featured Videos

American Academy of Ophthalmology — What is a pterygium and how does it form on the eye?

Eyecare Education — Step-by-step explanation of pterygium surgical excision and graft techniques.

Patient Stories — Personal account of managing surfer's eye and deciding on surgery.

Dr. Alan Mendelsohn — Key differences between pterygium and pinguecula explained clearly.

Ophthalmic Insights — What to expect during recovery after pterygium removal surgery.

Cornea Surgical — Surgical video: conjunctival autograft with fibrin glue fixation.

Eye Surgery Channel — Amniotic membrane transplantation for recurrent pterygium cases.

Vision Health Council — How UV-400 sunglasses protect the cornea and prevent pterygium.

Corneal Surgery Review — Evidence-based strategies to minimize pterygium recurrence after excision.

Academic Ophthalmology — How mitomycin C is used adjuvantly to reduce fibrovascular recurrence.

Dr. James Tsai — Grading pterygium severity and clinical decision-making for surgical timing.

Real Patient Experience — Before and after journey through pterygium diagnosis and surgical removal.

Ophthalmology Research — Subconjunctival bevacizumab as adjuvant therapy for pterygium management.

Ask an Eye Surgeon — Common patient questions about pterygium surgery answered by a corneal specialist.

Holistic Eye Health — Role of vitamins A, C, lutein, and omega-3s in ocular surface protection.

Eye Protection Guide — Choosing the right UV-400 sunglasses to prevent pterygium and other UV eye damage.